ArticleJAMA surgery2019
Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism.
Article in JAMA surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04761354 (Characteristics Predicting Clinically Relevant Reduction of Hypertension Following Adrenalectomy for Primary Aldosteronism), which is not on this map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characteristics Predicting Clinically Relevant Reduction of Hypertension Following Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Clinical and biochemical outcomes after adrenalectomy for primary aldosteronism in tertiary and quaternary referral centers: data from SOPRANO study.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Pooled it
- Assessment of performance of stratum-specific likelihood ratios of the aldosteronoma resolution score for predicting hypertension cure after adrenalectomy for primary aldosteronism: a systematic review and meta-analysis.Journal of human hypertension · 2023Pooled it
- Predictive factors of clinical success after adrenalectomy in primary aldosteronism: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- External validation of the PASO prediction score for primary aldosteronism.Endocrine connections · 2026Article
- Fewer Pills, Lower Bills: Antihypertensive and Cost Outcomes of Adrenalectomy in Primary Aldosteronism.Annals of surgical oncology · 2026Article
- Biochemical and clinical remission after adrenalectomy in patients with primary aldosteronism: a retrospective two-center study.Gland surgery · 2026Article
- Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines.Hypertension (Dallas, Tex. : 1979) · 2026Review
- Primary Aldosteronism Surgery Outcomes Under Current Blood Pressure Guidelines.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026Article
- Aldosterone and Cardiovascular Risk Across the Lifespan.Metabolites · 2025Review
- Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.European heart journal · 2025Review
- Novel predictive factors scoring model for persistent hypertension after adrenalectomy in patients with primary aldosteronism.Scientific reports · 2025Article
- Recurrence of primary aldosteronism 20 years after surgery: a case report.Journal of human hypertension · 2025Article
- Short- and long-term outcomes of adrenalectomy for primary aldosteronism in a single UK center: rear-mirror view.Hormones (Athens, Greece) · 2025Article
- Bilateral adrenal artery embolization for the treatment of idiopathic hyperaldosteronism: A proof-of-principle single center study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Predicting the resolution of hypertension following adrenalectomy in primary aldosteronism: Controversies and unresolved issues a narrative review.Langenbeck's archives of surgery · 2024Review
- Efficacy and safety of adrenal arterial embolization for primary aldosteronism: a systematic review and meta-analysis.Gland surgery · 2024Article
- The value of plasma metanephrine measurements during adrenal vein sampling.Endocrine connections · 2024Article
- Adrenalectomy for primary aldosteronism and its related surgical characteristics.Frontiers in endocrinology · 2024Review
- Diagnosis and management of primary hyperaldosteronism in patients with hypertension: a practical approach endorsed by the British and Irish Hypertension Society.Journal of human hypertension · 2024Review
- The left adrenal vein: An important direction for right adrenal venous sampling.Journal of clinical hypertension (Greenwich, Conn.) · 2023Article
Corrections and comments
- Commented on by
Authors and funding
37 authors at 18 institutions in 5 countries.
Funding
Abstract
Importance: In addition to biochemical cure, clinical benefits after surgery for primary aldosteronism depend on the magnitude of decrease in blood pressure (BP) and use of antihypertensive medications with a subsequent decreased risk of cardiovascular and/or cerebrovascular morbidity and drug-induced adverse effects. Objective: To evaluate the change in BP and use of antihypertensive medications within an international cohort of patients who recently underwent surgery for primary aldosteronism. Design, Setting, and Participants: A cohort study was conducted across 16 referral medical centers in Europe, the United States, Canada, and Australia. Patients who underwent unilateral adrenalectomy for primary aldosteronism between January 2010 and December 2016 were included. Data analysis was performed from August 2017 to June 2018. Unilateral disease was confirmed using computed tomography, magnetic resonance imaging, and/or adrenal venous sampling. Patients with missing or incomplete preoperative or follow-up data regarding BP or corresponding number of antihypertensive medications were excluded. Main Outcomes and Measures: Clinical success was defined based on postoperative BP and number of antihypertensive medications. Cure was defined as normotension without antihypertensive medications, and clear improvement as normotension with lower or equal use of antihypertensive medications. In patients with preoperative normotensivity, improvement was defined as postoperative normotension with lower antihypertensive use. All other patients were stratified as no clear success because the benefits of surgery were less obvious, mainly owing to postoperative, persistent hypertension. Clinical outcomes were assessed at follow-up closest to 6 months after surgery. Results: On the basis of inclusion and exclusion criteria, a total of 435 patients (84.6%) from a cohort of 514 patients who underwent unilateral adrenalectomy were eligible. Of these patients, 186 (42.3%) were women; mean (SD) age at the time of surgery was 50.7 (11.4) years. Cure was achieved in 118 patients (27.1%), clear improvement in 135 (31.0%), and no clear success in 182 (41.8%). In the subgroup classified as no clear success, 166 patients (91.2%) had postoperative hypertension. However, within this subgroup, the mean (SD) systolic and diastolic BP decreased significantly by 9 (22) mm Hg (P < .001) and 3 (15) mm Hg (P = .04), respectively. Also, the number of antihypertensive medications used decreased from 3 (range, 0-7) to 2 (range, 0-6) (P < .001). Moreover, in 75 of 182 patients (41.2%) within this subgroup, the decrease in systolic BP was 10 mm Hg or greater. Conclusions and Relevance: In this study, for most patients, adrenalectomy was associated with a postoperative normotensive state and reduction of antihypertensive medications. Furthermore, a significant proportion of patients with postoperative, persistent hypertension may benefit from adrenalectomy given the observed clinically relevant and significant reduction of BP and antihypertensive medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.